5 days ago Lyndra Therapeutics Presents Promising Phase 2 Data on Once-Weekly Oral Risperidone Treatment - - LYN-005, in Development for Schizophrenia Data demonstrate LYN-005 quickly reaches therapeutic levels in patients, provides sustained...
Mar 22 Amolyt Pharma Presents First Clinical Data for AZP-3601 AZP-3601 - its Parathyroid Hormone Analog for Hypoparathyroidism, at the Endocrine Society’s Virtual Annual Meeting (ENDO 2021) LYON,...
Mar 17 Mediar Therapeutics Adds New Investors As It Advances Anti-Fibrotic Treatments CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mediar Therapeutics today announced the completion of a seed extension funding round and welcomed...
Feb 17 Affinia Therapeutics Announces Addition of Gene Therapy Scientific and Medical Experts to Leadership Team to Advance Novel Gene Therapy Platform and Programs to the Clinic February 17, 2021...
Jan 7 Abcuro will take an anti-KLRG1 antibody into the clinic with new funding... Abcuro will take an anti-KLRG1 antibody into the clinic with new funding, and has big plans for another. A little over two years after...
Jan 7 Scorpion Therapeutics strikes major $162M funding round for 'precision oncology 2.0' Less than three months after breaking cover with an impressive $102 million series A, Scorpion has whipped up another major funding...
Jan 6 Amolyt Pharma Receives Orphan Drug Designation for AZP-3601 for the Potential Treatment of Hypoparat LYON, France and CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing...
Dec 9, 2020 ZielBio Appoints Dieter Weinand Executive Chair CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--ZielBio, Inc., an early-stage biotechnology company discovering new treatments for cancer and...
Dec 8, 2020 Amolyt Pharma Announces Research Collaboration with PeptiDream Amolyt and Peptidream will collaborate to optimize and evaluate growth hormone receptor antagonists to select a candidate for clinical...
Oct 26, 2020 Scorpion Therapeutics debuts with $108M to 'put the sting in cancer' When Gary Glick, Ph.D., left the CEO post at IFM Therapeutics, he didn’t know what was next. But he soon found himself on a plane with...
